Psychoactive Research chemicals are new synthetic substances that are structurally similar to the original drug, while being functional analogs. Research on the effects of, and treatment for, abuse of these drugs is limited due to the fact that they’re fairly new and have avoided mainstream notice. Research chemicals do not have a lot of human consumption data, and thus harm-reduction and special care should be taken if choosing to ingest them.
Psychedelics are drugs which cause profound changes in a one’s perceptions of reality, otherwise known as hallucinations. While under the influence of hallucinogens, users might see images, hear sounds or feel sensations. These chemicals offer some of the most intense psychological experiences and care should be taken when ingesting them.
This is a commonly used substance with well known and widely available human consumption data. This does not guarantee that the substance will be safe. The safety profile has been established based on usage data commonly available.
Disclaimer: Psychedelic drugs offer some of the most power and intense psychological experiences. Additionally these substances are illegal in many places. We understand that even though these substances are illegal, their use occurs frequently. We do not condone breaking of the law. By providing accurate information about these substances, we encourage the user to make responsible decisions and practice harm reduction.
Practice Harm Reduction. Proceed with Caution.
Also known as:
- 1H-Indol-4-ol, 3-[2
-(dimethylamino)eth[ACD/Index Name] yl]-, acetate (este r)
)ethyl]-1H-indol-4-[ACD/IUPAC Name] yl acetate
)ethyl]-1H-indol-4-[German][ACD/IUPAC Name] yl-acetat
- Acétate de 3-[2-(di
méthylamino)éthyl]-[French][ACD/IUPAC Name] 1H-indol-4-yle
o)ethyl]-1H-indol-4 -yl] acetate
ethyl)-1H-indol-4-y l acetate
)ethyl)-1H-indol-4-[ACD/IUPAC Name] yl-acetate
)ethyl]-1H-indol-4- yl acetate fumarate salt
hyltryptamine free base
hyltryptamine fumar ate
hyltryptamine, free base
- MFCD04279029[MDL number]
)ethyl)-1H-indol-4- yl acetate
A prodrug for Psilocin with extremely similar effects as Mushrooms.
It is a structural analog of psilocybin, the active ingredient in psilocybin mushrooms (magic mushrooms). Like psilocybin, it is thought to produce its effects primarily by binding to serotonin receptors in the brain; however, the precise mechanism is not fully understood. The synthesis of 4-AcO-DMT was first reported in 1963 by and Franz Troxler as part of an investigation into psilocin analogs.
However, its pharmacology and subjective effects were not explored. A paper authored by David E. Nichols in 1999 proposed it as a potentially useful alternative to psilocybin for pharmacological research due to lower cost of synthesis.
Reports of recreational use began to surface shortly after its appearance on the online research chemical market in the 2010s. Subjective effects are reported to be nearly identical to those of psilocybin mushrooms and include geometric visual hallucinations, time distortion, enhanced introspection, euphoria, and ego loss. 4-AcO-DMT is theorized to act as a prodrug to psilocin in a similar manner as psilocybin, which may account for this similarity.
4-AcO-DMT’s classical psychedelic effects and favorable tolerability profile has led it to become popular among novel psychoactive substance users who seek mystical or entheogenic experiences. Very little data exists on the pharmacology, metabolism, and toxicity of 4-AcO-DMT. While it is believed to have a favorable safety profile similar to that of psilocybin mushrooms (which are known to be physiologically non-toxic) there is currently no data to support this claim.
It is highly advised to use harm reduction practices if using this substance.
You can help by expanding it.
4-AcO-DMT and several other esters of psilocin were patented on January 16, 1963 by Sandoz Ltd. via Albert Hofmann & Franz Troxler. However, its pharmacology and subjective effects were not investigated.
It is unknown when 4-AcO-DMT’s effect in humans were first explored.
Tryptamines share a core structure that consists of a bicylic indole heterocycle attached at R3 to a terminal amino group via an ethyl side chain.
4-AcO-DMT is substituted at R4 of its indole heterocycle with an acetoxy (-AcO) functional group CH3COO−.
It also contains two methyl groups CH3- bound to the terminal amine RN of the ethyl side chain. 4-AcO-DMT is the acetate ester analog of psilocin (4-HO-DMT) and the N-substituted methyl homolog of 4-AcO-MET.
It is the O-acetylated form of psilocin, whereas psilocybin is the O-phosphorylated form.
|Avg. Mass||246.3049 Da|
|Monoisotopic Mass||246.136826 Da|
|4-AcO-DMT Duration Data|
Interactions and Synergies
There are no existing interaction or synergy data for this drug.
|Come up||Slow comeup, some users report it taking nearly 2 hours until first effects are felt.|
|Effects||4-aco-dmt is a psilocin analog, so effects are very similar to mushrooms. Some users report very little difference between 4-aco-dmt and mushrooms.|
|Marguis Test Result|
The psychedelic effects of 4-AcO-DMT are believed to come from its activity as a partial agonist for the 5-HT2A receptor. However, the role of these interactions and how they result in the psychedelic experience is the subject of ongoing scientific investigation. In the body, 4-AcO-DMT is suspected to be deacetylated into psilocin during first pass metabolism, by the acidic conditions in the stomach, and as it passes through the liver.
Users frequently describe 4-AcO-DMT as being extremely similar to psilocybin mushrooms. It is generally described as euphoric, gentle, warm, and colorful. Visuals are reported by some users to be brighter and more neon in a manner reminiscent of DMT. It is also reported to be less nauseating than psilocybin mushrooms, which may be due to the fact that it does not require digesting mushroom matter.
- Sedation - 4-AcO-DMT is considered by most to be relaxing, stoning and mildly sedating. This sense of sedation is often accompanied by compulsive yawning.
- Perception of bodily heaviness
- Spontaneous bodily sensations - The general "body high" of 4-AcO-DMT can be described as a pleasurable, warm, soft and all-encompassing tingling sensation. This maintains a consistent presence that steadily rises with the onset and hits its limit once the peak has been reached. Once the peak of the experience or sensation is reached it can produce feelings of pronounced physical and cognitive euphoria along with tranquility, a sense of lethargy or sedation, or total immobilization depending on the dose.
- Tactile enhancement - This effect is less prominent than with that of LSD or 2C-B but is still present and unique in its character. It is repeatedly described as feeling very primitive in its nature often times with the small hairs on the user's arms or legs feeling slightly itchy or even ticklish against the skin.
- Changes in felt bodily form - This effect is often accompanied by a sense of warmth and usually occurs around or directly after the peak of the experience. Users can feel as if they are physically part of or conjoined with other objects in a seamless continuity. This is usually reported as feeling comfortable, tranquil and mindful, though it can also manifest in the form of bodily tension.
- Changes in felt gravity
- Nausea - This effect can be greatly lessened or even completely avoided if the individual has an empty stomach prior to ingestion. It is sometimes recommended that one either refrain from eating for approximately 6 to 8 hours before-hand, or to eat a light meal 3 to 4 hours before if the user is feeling physically fatigued and undernourished. The nausea produced by 4-AcO-DMT is generally considered to be much less prominent than it is with psilocybin mushrooms, perhaps owing to the fact that there is no fungal-matter the body has to digest when the isolated synthetic form is consumed.
- Temperature regulation suppression - 4-AcO-DMT can cause fluctuates in the user's internal sense of temperature, which can manifest as sudden bouts of uncomfortable coldness or warmth, which is why a climate-controllable environment is strongly recommended.
- Muscle contractions - The muscle contractions that can occur on 4-AcO-DMT tend to be transient and benign feeling in nature, compared to many other tryptamines, phenethylamines and lysergamides.
- Muscle relaxation
- Excessive yawning - This effect seems to be uniquely pronounced among psilocin and related tryptamines. It can occur to a lesser degree on LSD and very rarely on psychedelic phenethylamines like mescaline. It typically occurs in conjunction with watery eyes.
- Watery eyes
- Frequent urination
- Gustatory enhancement
- Olfactory enhancement
- Olfactory hallucination
- Pupil dilation
- Runny nose
- Increased salivation
- Teeth grinding - This effect is considerably less intense when compared with substances like MDMA when it occurs.
- Brain zaps - This effect is uncommon and thought to only occur in those who are predisposed to them. It is much less prevalent and intense than those that occur with serotonin releasing agents such as MDMA.
- Seizure - This is a rarely observed effect and is thought to primarily be a risk factor in those already predisposed to them, particularly while in physically taxing conditions such as being overheated, dehydrated, undernourished or fatigued.
The cognitive effects and general head space of 4-AcO-DMT are commonly described as extremely relaxing, profound and slow-paced in style when compared to other commonly used psychedelics, such as LSD or 2C-B, which have a distinct energetic and stimulating push. It is also generally regarded as being notably more lucid than psilocybin mushrooms.
- Analysis enhancement - This effect is consistent in its manifestation with a tendency to be outrospective in nature, but may also manifest as introspection depending on one's set and setting.
- Novelty enhancement
- Immersion enhancement
- Creativity enhancement
- Conceptual thinking
- Personal bias suppression
- Multiple thought streams
- Emotion enhancement - This effect can be described as being more prominent, consistent and profound when compared to other traditional psychedelics such as mescaline or LSD. This can lead to strong feelings of compassion, urgency and even completely sporadic moments of intense emotional significance that can also be periodically affected by enhancement and suppression cycles. Many reports suggest, however, that that the experience is not as consistently emotionally-charged as that produced by consuming psilocybin mushrooms.
- Simultaneous emotions
- Empathy, affection, and sociability enhancement - This effect differs from MDMA and other entactogens in that it isn't as central to the experience, feels less forced and more natural and is experienced at a less consistent rate. While the substance consistently produces heightened empathy and affection, sociability enhancement in particular only occurs rarely if at all due to the language and memory suppressing cognitive effects that accompany the experience.
- Language suppression - This effect can be described as a perceived inability or general unwillingness to talk aloud despite feeling perfectly capable of formulating coherent thoughts within one's internal narrative. It is much more common among inexperienced users.
- Enhancement and suppression cycles - This can be described as constant waves of extremely stimulated and profound thinking which are spontaneously surpassed in a cyclic fashion by waves of general thought suppression and mental intoxication. These two states seem to switch between each other in a consistent loop once every 20 to 60 minutes when present.
- Increased sense of humor
- Increased music appreciation
- Cognitive euphoria
- Memory suppression
- Feelings of impending doom - This effect is usually only experienced during the come up phase but typically completely passes or subsides once the primary effects begin. It should be noted that this effect is relatively consistent and normal for psilocin and related tryptamines which is why a positive and well-informed mindset is key. Less regularly this aspect can also occur during the peak but will most often be met after with sensations of euphoria and rejuvenation.
- Rejuvenation - While this effect can occur spontaneously at any point, it typically follows a difficult phase of the experience, if not the entire experience itself.
- Thought connectivity
- Thought deceleration
- Thought organization
- Thought loops
- Time distortion
- Déjà vu
- Ego replacement - Although this effect is rare and more likely to occur with certain psychedelics like DMT or ayahuasca, it can still occur spontaneously, typically with higher doses.
- Personality regression - While this effect is not typically observed, it can still spontaneously manifest and is thought to depend primarily on the user's set and setting.
- Drifting (melting, flowing, breathing and morphing) - In comparison to other psychedelics, this effect can be described as highly detailed, realistic, slow and smooth in motion and static in appearance.
- Colour shifting
- Colour tinting
- Visual haze
- After images
- Symmetrical texture repetition
- Perspective distortions
- Depth perception distortions
- Environmental orbism
- Scenery slicing
- Environmental patterning
The visual geometry of 4-AcO-DMT can be described as more similar in appearance to that of psilocin, low-medium dose DMT, and ayahuasca as opposed to LSD or 2C-B. It can be comprehensively described through its variations as intricate in complexity, abstract in form, organic in style, structured in organization, brightly lit and multicoloured in scheme, glossy in shading, soft in edges, large in size, slow in speed, smooth in motion, rounded in corners, non-immersive in-depth and consistent in intensity. They can be described as having a "natural" feel and, at higher doses, are significantly more likely to result in states of Level 8B visual geometry over Level 8A.
4-AcO-DMT produces a full range of high level hallucinatory states in a fashion that is more consistent and reproducible than that of many other commonly used psychedelics. These effects generally include:
- Machinescapes - This effect is a rare effect that typically only occurs at very strong to heavy doses, and not as consistently as with notably visual psychedelics like DMT, ETH-LAD, and 2C-P, and atypical psychedelics like salvia.
- Internal hallucination (autonomous entities; settings, sceneries, and landscapes; perspective hallucinations and scenarios and plots) - This effect is very consistent in dark environments at appropriately high doses. They can be comprehensively described through their variations as lucid in believability, interactive in style, new experiences in content, autonomous in controllability, geometry-based in style and almost exclusively of a personal, religious, spiritual, science-fiction, fantasy, surreal, nonsensical or transcendental nature in their overall theme.
- External hallucination (autonomous entities; settings, sceneries, and landscapes; perspective hallucinations and scenarios and plots) - These are more common within dark environments and can be comprehensively described through their variations as lucid in believability, interactive in style, new experiences in content, autonomous in controllability, geometry-based in style and almost exclusively of a personal, religious, spiritual, science-fiction, fantasy, surreal, nonsensical or transcendental nature in their overall theme.
- Synaesthesia - In its fullest manifestation, this is a very rare and non-reproducible effect. Increasing the dose can increase the likelihood of this occurring, but seems to only be a prominent part of the experience among those who are already predisposed to synaesthetic states.
- Dosage independent intensity
4-AcO-DMT is not listed under any international drug schedules such as the UN Convention on Psychotropic Substances. As a result, it exists in a legal grey area in many countries, meaning that while it is not specifically illegal individuals may still be charged for its possession under certain circumstances such as under analogue laws and with the intent to sell or consume.
- Nichols, D. E., & Frescas, S. (1999). Improvements to the synthesis of psilocybin and a facile method for preparing the O-acetyl prodrug of psilocin. Synthesis, 1999(6), 935-938.
- US patent 3075992, Hofmann A, Troxler F, "Esters of indoles", assigned to Sandoz Ltd.
- Armstrong, B. D., Paik, E., Chhith, S., Lelievre, V., Waschek, J. A., & Howard, S. G. (2004). Potentiation of (DL)‐3, 4‐methylenedioxymethamphetamine (MDMA)‐induced toxicity by the serotonin 2A receptior partial agonist d‐lysergic acid diethylamide (LSD), and the protection of same by the serotonin 2A/2C receptor antagonist MDL 11,939. Neuroscience Research Communications, 35(2), 83-95. https://doi.org/10.1002/nrc.20023
- Potentiation of MDMA-induced dopamine release and serotonin neurotoxicity by 5-HT2 receptor agonists | https://indiana.pure.elsevier.com/en/publications/potentiation-of-34-methylenedioxymethamphetamine-induced-dopamine
- Ecstasy induces apoptosis via 5-HT(2A)-receptor stimulation in cortical neurons. | https://www.ncbi.nlm.nih.gov/pubmed/17572501
- Talaie, H.; Panahandeh, R.; Fayaznouri, M. R.; Asadi, Z.; Abdollahi, M. (2009). "Dose-independent occurrence of seizure with tramadol". Journal of Medical Toxicology. 5 (2): 63–67. :10.1007/BF03161089. 1556-9039.
- "Sechste Verordnung über die den Betäubungsmitteln gleichgestellten Stoffe" (in German). Bundesanzeiger Verlag. Retrieved December 10, 2019.
- "Anlage I BtMG" (in German). Bundesministerium der Justiz und für Verbraucherschutz. Retrieved December 10, 2019.
- "§ 29 BtMG" (in German). Bundesministerium der Justiz und für Verbraucherschutz. Retrieved December 10, 2019.
- Misuse of Drugs Act 1971 (Legislation.gov.uk) | http://www.legislation.gov.uk/ukpga/1971/38/schedule/2/part/I/paragraph/3
- 1717 CheMall HE052609
- 1717 CheMall HE194317
- abcr AB464220
- ABI Chemicals AC2A013G8
- AK Scientific Z1701
- AKos AKOS025149599
- Alfa Chemistry 92292-84-7
- Alichem A199011525
- American Custom Chemicals Corp CHM0296982
- Angene AG-A-70925
- Anward ANW-60689
- Ark Pharm, Inc. AK-84418
- Aurora Fine Chemicals A14.515.307
- Aurora Fine Chemicals K18.911.161
- BGS International BG03620650
- BGS International BG04264988
- Biosynth A-0279
- ChemIDplus 92292847
- Chemspace CSC016999246
- eNovation Chemicals K39261
- EPA DSSTox DTXCID80161446
- Erowid 4-Acetoxy-DMT
- FDA UNII - NLM 8BLF220HX1
- Fluorochem 224431
- iChemical EBD4101
- LabNetwork LN01358105
- Letopharm LT08-00350
- Mcule MCULE-3211903653
- Syntharise Chemical SRISEC019
- Tractus Company Limited
- Wikidata Q3491364
- Wikipedia O-Acetylpsilocin
Information made possible with:
- PsychonautWiki is a community-driven online encyclopedia that aims to document the field of psychonautics in a comprehensive, scientifically-grounded manner.
- Erowid is a non-profit educational & harm-reduction resource with 60 thousand pages of online information about psychoactive drugs
- PubChem National Center for Bio Informatics
- Chemspider is a free chemical structure database providing fast access to over 34 million structures, properties and associated information.
Additional APIs were used to construct this information. Thanks for ChemSpider, NCBI, PubChem etc.
Data is constantly updated so please check back later to see if there is any more available information on this substance.